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A New Era in Asthma Management:
Assessment of Asthma Control
Kevin R. Murphy, MD; Joel Solis, MD

BURDEN OF DISEASE
Asthma is recognized as a chronic, heterogenous disease
characterized by airway inflammation and a history of respiratory symptoms (eg, wheeze, shortness of breath, chest
tightness, or cough) that vary over time and in intensity.1
Variations are often triggered by factors such as exercise,
allergen or irritant exposure, change in weather, or viral
respiratory tract infections. Asthma symptoms and airflow
limitation may resolve spontaneously or in response to treatment. Symptoms may be absent for weeks or months, yet airway hyperresponsiveness related to chronic airway inflammation usually persists.1
Asthma is a common disease in children, adolescents,
and adults that results in substantial morbidity and utilization
of health care resources.2 In 2018, there were an estimated 5.5
million children and 19.2 million adults in the United States
with asthma, of whom 45% had ≥1 asthma attack.2 In 2016,
there were nearly 10 million office visits with asthma as a
primary diagnosis.2 One-third (33.1%) of adults with asthma
report their health as fair or poor.3 Anxiety, depression, and
asthma control are independent predictors of diminished
health-related quality of life in people with asthma.4
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The economic burden of asthma, including costs
incurred by absenteeism and mortality, was estimated at
$82 billion in 2013.5 By comparison, the total economic
burden – including lost productivity – has been estimated
at $330 billion for heart disease and stroke and $327 billion
for diabetes.6 The 20-year estimated burden of direct and
indirect costs associated with asthma is $964 billion, with
a loss of 15.5 million quality-adjusted life-years in adolescents and adults.7
A key factor contributing to the burden of disease
associated with asthma is poor adherence to treatment by
patients.8-10 A variety of additional factors contribute, including limited understanding among patients about asthma and
its treatment, as well as poor patient-clinician communication.11-13 Discordance regarding asthma control is common
between patients and clinicians.14 Patients often overestimate
their asthma control15 or may tolerate symptoms indicative of
poor control based on the belief that the symptoms are part
of living with asthma.16 Collectively, these factors contribute
to suboptimal asthma control.

ASSESSING ASTHMA CONTROL
Asthma control means the extent to which the effects of
asthma either can be seen in the patient or have been
reduced or resolved by treatment. Asthma control has 2
domains: symptom control and risk factors for future poor
outcomes, particularly flare-ups (exacerbations). It is important to assess the patient’s future risk for exacerbations, even
when symptom control is good. Risk factors for exacerbations
that are independent of symptom control include a history of
≥1 exacerbation in the previous year, socioeconomic disadvantages, poor treatment adherence, incorrect inhaler technique, low lung function, smoking, and blood eosinophilia.1
Many tools are available to assess asthma control and
are listed in the TABLE.17-26 Of those tools, the Asthma Impairment and Risk Questionnaire (AIRQ) and Asthma Control
Test (ACT) are validated for patients age ≥12 years and have
numerically scored questions providing total scores and cut
points for varying levels of asthma control. The ACT (FIGURE 1)
is limited to assessing symptom control with no direct measure of future risk.19,20,23
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TABLE.

Tools for assessing asthma control
Focus

Tool
Asthma APGAR

17,18

Symptoms

Risk

Target patient
age (y)

Administered by

No. of
items

Recall time

ü

ü

5-45

Self

6

2 wk (symptoms and risk)

Self

7

1 wk

Asthma Control
Questionnaire19

ü

≥11

ü

6-10

HCP

7

1 wk

Asthma Control Test20

ü

≥12

Self

5

4 wk

Asthma Control and
Communication
Instrument21

ü

ü

≥12

Self

12

Since last visit (symptoms
and risk)

Asthma Impairment and
Risk Questionnaire22

ü

ü

≥12

Self/HCP

4-11

10

2 wk (symptoms);
1 year (risk)

Self/parent

7

4 wk (symptoms);
1 year (risk)
2 wk (symptoms);
2 mo (risk)

Childhood Asthma
Control Test23

ü

Composite Asthma
Severity Index24

ü

ü

6-17

HCP

8

Pediatric Asthma Control
and Communication
Instrument25

ü

ü

≤21

Self/parent

12

2 wk (symptoms); since last
visit/2 mo (risk)

Test for Respiratory and
Asthma Control in Kids26

ü

ü

<5

Parent

5

4 wk (symptoms);
12 mo (risk)

Abbreviations: HCP, health care professional.

ASTHMA IMPAIRMENT AND RISK QUESTIONNAIRE
To address the gaps in commonly used tools for assessing
asthma control, the Asthma Impairment and Risk Questionnaire (AIRQ) was recently developed.22 The AIRQ was
devised using a modified Delphi process by a network of 190
US scientific experts and primary and specialty care clinicians with diverse practice experiences in geographic areas
representing a high burden of disease. The AIRQ was validated using patients (N=442) from geographically diverse US
allergy/immunology and pulmonology clinics. The symptom
control domain of the AIRQ was validated against the ACT,
whereas the future risk domain was validated against the
patient’s prior-year exacerbations as documented in their
medical record. From the initial 15 questions that assessed
symptom control and risk, the final questionnaire includes
10 dichotomous (yes or no) questions, 7 focusing on symptom control and 3 on future risk (FIGURE 2).49 The 10 questions
evaluate symptoms, social and physical activities, exacerbations, related health care resource utilization, perception of
asthma control, and use of rescue medications. The AIRQ
score ranges from 0 to 10. A score of 0 or 1 indicates asthma is
well-controlled, whereas a score of 2 to 4 indicates asthma is
not well-controlled. A score of 5 to 10 indicates asthma is very
poorly controlled.
The AIRQ performed exceptionally well, including a
superior comparison to the ACT.20,22 Importantly, as shown in
the AIRQ validation study, 31% of patients classified as wellcontrolled by ACT score (≥20) had suffered ≥1 exacerbation

in the previous year, suggesting limitations in using ACT as
a sole measure of asthma control.22 Inclusion of the wide
array of items in AIRQ to assess both symptom control and
future risk identified many patients with exercise limitations
and exacerbations that were characterized by acute treatment with oral corticosteroids or emergency department/
unplanned office visits, events that are not assessed by the
ACT or many other asthma control tools for patients age ≥12
years.

MANAGEMENT OF PATIENTS WITH
UNCONTROLLED ASTHMA
The most up-to-date recommendations for managing
patients with uncontrolled asthma (discussed below) were
released by Global Initiative for Asthma (GINA) in 2020.1
Updated recommendations by the National Asthma Education and Prevention Program (NAEPP) Expert Panel Report-4
(EPR-4) have been circulated in draft form and are currently
being finalized.
Patients found to have uncontrolled asthma should continue to receive care that meets their clinical and personal
needs and capabilities. A key step in managing a patient with
uncontrolled asthma is to confirm the asthma diagnosis. If
not done as part of assessing asthma control, lung function
should be measured. In addition, reevaluation of asthma
control is appropriate to ensure that the treatment plan is
consistent with recommended evidence-based therapy.
Attention should be paid to verify that all modifiable
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FIGURE 1.

Asthma Control Test48

[https://www.asthma.com/additional-resources/asthma-control-test.html]
[This Web Site has been developed as a service of GlaxoSmithKline. Like any other service, in spite of our (GSK) best efforts the information in this Web Site may become out of date
over time. Nothing on this Web Site should be construed as the giving of advice or the making of a recommendation and it should not be relied on as the basis for any decision or
action. It is important that you rely only on the advice of a health care professional to advise you on your specific situation. GlaxoSmithKline accepts no liability for the accuracy or
completeness or use of, nor any liability to update, the information contained on this Web Site. These materials are provided “AS IS” WITHOUT WARRANTY OF ANY KIND, EITHER
EXPRESSED OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT. Some jurisdictions do not allow the exclusion of implied warranties, so the above exclusion may not apply to you.]
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FIGURE 2.

Asthma Impairment and Risk Questionnaire49

[http://www.airqscore.com]
[AIRQ™ is a trademark of AstraZeneca. The AIRQ™ is reproduced with permission from AstraZeneca. AstraZeneca is the copyright owner of the AIRQ™. However, third parties will
be allowed to use the AIRQ™ free of charge. The AIRQ™ must always be used in its entirety. Except for limited reformatting the AIRQ™ may not be modified or combined with other
instruments without prior written approval. The ten questions of the AIRQ™ must appear verbatim, in order, and together as they are presented and not divided on separate pages.
All copyright and trademark information must be maintained as it appears on the bottom of the AIRQ™ and on all copies. The layout of the final authorized AIRQ™ may differ slightly,
but the item wording will not change.]
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FIGURE 3.

Modifying treatment in adults and adolescents with uncontrolled asthma1

Abbreviations: BDP, beclomethasone dipropionate; FEV1, forced expiratory volume in 1 second; HDM SLIT, house dust mite sublingual immunotherapy; ICS, inhaled corticosteroid; IgE, immunoglobulin E; IL5, interleukin-5; IL5R, interleukin-5 receptor; LABA, long-acting beta2-agonist; LTRA, leukotriene receptor antagonist; OCS, oral corticosteroid; SABA, short-acting beta2-agonist.
© 2020, Global Initiative for Asthma, available from ginasthma.org, published in Fontana, WI, USA.

risk factors have been identified and appropriate treatment
instituted. This strategy is particularly important for risk
factors that do not require or respond to a step-up in controller treatment. Examples include poor inhaler technique, suboptimal treatment adherence, home and workplace atopic
and irritant triggers, tobacco use or exposure, and comorbidities such as gastroesophageal reflux disease, nasal polyposis,
obesity, and sleep apnea.
Patient understanding of asthma, treatment goals, and
treatment options should be assessed and reinforced with
further education. A guide for patients and families is available from the National Heart, Lung, and Blood Institute
(https://www.nhlbi.nih.gov/files/docs/public/lung/SoYouHaveAsthma_PRINT-reduced-filesize.pdf). Patients should
be educated about the importance of the use of anti-inflammatory medications, because only 39% of adults and 40% of
children with asthma use a long-term control medication.27
In addition, patient education should include the importance of reducing the risk of exposure to allergens or other
sensitizing agents.1
The patient’s familiarity with their written asthma
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action plan should be assessed routinely, as this is an indicator of the patient’s ability to self-manage their asthma.
Patients should be invited to share difficulties they may be
having with the action plan or any other issues that may
affect treatment adherence. If difficulties are identified,
focus a collaborative discussion on finding a solution that
is acceptable to the patient and that they are able and willing to implement. Sample written action plans are available
from the National Heart, Lung, and Blood Institute (https://
www.nhlbi.nih.gov/health-topics/all-publications-andresources/asthma-action-plan) and GINA (https://ginasthma.org/wp-content/uploads/2019/01/GINA-Implementation-Toolbox-2019.pdf ).
Objective assessment of inhaler technique is especially
important because proper technique has a direct impact
on patient health outcomes and treatment tolerability.28
Because administration errors with inhaled medications
by patients are common, and clinicians are often unfamiliar with proper administration technique,29-33 the use of
authoritative patient education resources demonstrating
proper inhaler technique – such as those by the Centers for
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Disease Control and Prevention – is recommended (https://
www.cdc.gov/asthma/inhaler_video/default.htm).

PHENOTYPES AND
BIOMARKERS
The heterogeneous nature of asthma and the many clusters of
demographic, clinical, and/or pathophysiologic characteristics
point to the importance of recognizing asthma phenotypes and
endotypes in patients with uncontrolled asthma.1,34 Identifying
the asthma phenotype is especially important for patients with
moderate or severe uncontrolled asthma because some phenotype-specific treatments are available. For example, omalizumab is indicated for allergic asthma, whereas benralizumab,
dupilumab, mepolizumab, and reslizumab are indicated for
the eosinophilic phenotype.
Two peripheral biomarkers (Immunoglobulin E [IgE]
and eosinophils) are particularly helpful in identifying
asthma phenotype and guiding treatment. IgE is the predominant biomarker for allergic asthma that is produced early in
the allergic cascade.35 The serum IgE level correlates closely
with the presence and severity of asthma in adults, adolescents, and children.36,37
Owing to the inflammatory nature of asthma, eosinophils are recruited through the complex interaction of cytokines and other inflammatory mediators.38,39 The blood
eosinophil count is more closely correlated with risk of
asthma exacerbations.40 Symptom severity is increased in
eosinophilic asthma, although symptom severity is not identified exclusively with eosinophilia.35,41-43

KEY ASTHMA TREATMENT RECOMMENDATIONS
Global Initiative for Asthma
GINA was implemented in 1993 to develop a network of
individuals, organizations, and public health officials for the
dissemination of information related to the care of patients
with asthma.44 Another key purpose of GINA was to provide
a mechanism to incorporate the results of scientific evidence
into asthma care, leading to the first GINA report in 1995,
developed in collaboration with the National Heart, Lung, and
Blood Institute. The report has been updated several times,
and recently on a yearly basis, to reflect the totality of the
evolving evidence. Consequently, the GINA report provides
comprehensive recommendations for the diagnosis and treatment of patients with asthma.1 Key recent changes include the
recommendations that all adults and adolescents should be
treated with an inhaled corticosteroid (ICS) to reduce the risk
of severe exacerbations. In addition, treatment with only a
short-acting beta2-agonist is no longer recommended.
Specific recommendations for step-up therapy are
beyond the scope of this article, as recommendations

depend on the patient’s current therapy and asthma control. Nonetheless, step-up therapy involves either increasing
the dose of the current controller therapy or adding another
controller medication. For example, a patient aged ≥12 years
whose asthma is uncontrolled with the combination of a lowdose ICS plus a long-acting beta2-agonist may benefit from
increasing to a medium-dose ICS plus a long-acting beta2agonist (FIGURE 3).1 Discussions with a patient about step-up
therapy should consider affordability, as asthma care in the
United States is associated with high rates of cost-related
underuse of medications. Although the reason is unclear,
suboptimal adherence to asthma medications does not
appear to be directly related to income.45 Any step-up should
be regarded as a therapeutic trial, and the response reviewed
after 2 to 3 months.1 In some cases, for example, during viral
infection or seasonal allergen exposure, the duration of stepup therapy may be only 1 to 2 weeks.
National Asthma Education and Prevention Program
The NAEPP was initiated in 1989 to address the growing
health problem of asthma in the United States.46 From the
beginning, the NAEPP has involved a wide variety of stakeholder groups and organizations with the general goals to
raise awareness among all asthma stakeholders about the
importance of asthma, as well as to promote effective, evidence-based treatment so as to reduce the disease burden.
The first guideline report was published in 1991, with subsequent updates and comprehensive revisions. The last comprehensive revision was the Expert Panel Report-3 in 2007.
The EPR-4, which is a limited revision that focuses on 6 topics, is being finalized.47

SUMMARY
Asthma is often uncontrolled in patients of all ages and is
frequently unrecognized, resulting in a significant burden
of disease. Consequently, assessing asthma control at every
opportunity is critical. A wide variety of tools to assess asthma
control are available; however, many have clinically important limitations to their use. The AIRQ was developed recently
to be more widely applicable, by assessing both symptom
control and future risk domains. In patients with uncontrolled asthma, step-up therapy is generally required using
evidence-based recommendations for treatment provided in
the GINA 2020 report and soon-to-be-released NAEPP EPR-4
report. ●
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